

Information

Extended deadline:
Early bird price until April 30, 2019

Tickets*

Category	Non-Member	Member and nNGM-Partner
Early Bird (deadline: April 30, 2019)	349,00 €	199,00 €
Late Bird (deadline: June 25, 2019)	449,00 €	249,00 €
On-site	499,00 €	299,00 €
Student	89,00 €	

*including social get together

Hotels

For your stay in Cologne we have reserved room contingents in different hotels.

Your Contact:
Kongress- und Kulturmanagement GmbH
Katharina Friedrich
Hotelmanagement
Phone: +49 3643 2468-142
Fax: +49 3643 2468-31
Mail: hotel@kukm.de

Arrival Information

Distances, Prices and Transportation


Main Station: 1 km
Cologne/Bonn Airport: 15 km

Taxi Fares

From Main Station: appx. 10,00 €
From Airport: appx. 30,00 €

Busses and Trams

From Main Station:
Busroute 132 to stop "Heumarkt"
Busroute 133 to stop "Heumarkt"
Tramway 5 to stop "Heumarkt"
From Airport:
S13 to stop "Deutz", take tramway 1,7 or 9 to stop "Heumarkt"



Conference Venue

Maritim Hotel
Heumarkt 20, D-50667 Cologne



2nd Cologne Conference on Lung Cancer

26 - 27 JUNE 2019 | GERMANY

Register now:
www.cologne-clc.com



Program

Contact

Lisa Dinter
Kongress- und Kulturmanagement GmbH
Phone: +49 3643 2468-147
Fax: +49 3643 2468-31
Mail: lisa.dinter@kukm.de

Juliane Süptitz
University Hospital of Cologne
National Network Genomic Medicine
Phone: +49 221 478-96532
Fax: +49 221 478-3531
Mail: juliane.sueptitz@uk-koeln.de

Registration and more information:
www.cologne-clc.com

Follow us on twitter:
[@CCLC2019](https://twitter.com/CCLC2019)

2nd Cologne Conference on Lung Cancer

26 - 27 June 2019



nNGM | National Network Genomic Medicine Lung Cancer



Network Genomic Medicine Lung Cancer



UNIKLINIK KÖLN

LungCancerGroup Cologne



CIO Center for Integrated Oncology Köln Bonn

Dear Participants,

We are looking forward to welcoming you to the 2nd Cologne Conference on Lung Cancer, taking place from June 26 – 27, 2019 in the Maritim Hotel.

The pace at which new therapies for lung cancer are being developed is breathtaking. Novel strategies include newer generations of inhibitors targeting mutant kinases as well as more refined modes of applications of immunotherapy. However, with each new success we also face our limits (in particular, because of acquired resistance), and cure still remains out of reach for most of our patients. Furthermore, physicians are increasingly being overwhelmed with the complexity of the boundaries of the various treatment strategies. We feel strongly that improvements of efficacy will be achieved only through a more precise understanding of the mechanisms underlying malignant transformation, clonal evolution and the interaction of tumor cells with their microenvironment. Furthermore, transferring this knowledge into clinical routine will require a continuous and intense dialogue of basic scientists, physician scientists and clinicians.

We are expecting a highly interactive meeting sparked by the panel of internationally renowned speakers, who will discuss their latest research developments. We would like to thank all guest speakers for their active participation and engagement.

We are looking forward to welcoming you and wish all participants who have to travel to Cologne a pleasant journey.

Sincerely yours,



Charles Swanton



Roman Thomas



Reinhard Büttner



Jürgen Wolf

Program

Wednesday, 26 June 2019

8.15 am	Welcome Charles Swanton, Roman Thomas, Reinhard Büttner, Jürgen Wolf
8.30 - 10.30 am	Session I: Immune Checkpoint Inhibitors: Resistance and Combinations Chairs: Kwok Wong, Jürgen Wolf
	Solange Peters: ICI combinations: effective alternatives to chemotherapy?
	Martin Reck: Patients relapsing after ICI 1 st line therapy: new therapeutic strategies
	Sergio Quezada: Mechanisms of response to CTLA4 and PD1 antibody therapy
	Martin Sebastian, Kwok Wong: Perspective on clinical management of challenging patients: illustration by a real-life case
	10.30 - 11.00 am: Coffee Break

11.00 am - 1.00 pm	Session II: Immunotherapy: Beyond PD-1 Chairs: Martin Sebastian, Solange Peters
	Charles Swanton: Lung cancer evolution and Immune Evasion
	Michael Hölzel: Targeting the tumor microenvironment to improve anti-tumor immunity
	Kwok Wong: Mechanistically informed combination immunotherapy
	Ugur Sahin: Individualized tumor vaccines
	1.00 - 2.00 pm: Lunch

2.00 - 4.00 pm	Session III: News from the kinome (I) Chairs: Wilfried Eberhard, Ben Solomon
	Lecia Sequist: EGFR mutant lung cancer: treatment strategies after failure of 3 rd gen. EGFR-TKIs
	Pasi Jänne: KRAS mutant lung cancer: light at the end of the tunnel?
	Alice Shaw: ALK positive lung cancer: choosing the optimal sequence
	Oliver Gautschi & Egbert Smit: Perspective on clinical management of challenging patients: illustration by a real-life case
	4.00 - 4.30 pm: Coffee Break

4.30 - 6.30 pm	Session IV: Clonal Evolution and Genetic Heterogeneity Chairs: Charles Swanton, Reinhard Büttner
	Mariam Hanjani: Clinical implications of tumor heterogeneity
	Martin Peifer: Evolutionary dynamics and drug resistance
	Maximilian Diehn: Circulating tumor DNA
	Monte Winslow: Molecular Determinants of Lung Cancer Initiation and Growth
6.30 - 7.30 pm	Tony Mok: Keynote Lecture
	8.00 pm: Social Event: SkyKöln

Thursday, 27 June 2019

8.30 - 11.00 am	Session V: News from the Kinome (II) Chairs: Frank Griesinger, Pasi Jänne
	Ben Solomon: Upcoming new targets
	Robert Doebele: Acquired resistance in lung cancers bearing kinase gene rearrangements
	Daniel Rauh: The next next generation of kinase inhibitors
	Rafael Rosell: Immunotherapy in oncogene-addicted lung cancer
	10.30 - 11.00 am: Coffee Break

11.00 am - 1.00 pm	Session VI: Small Cell Lung Cancer Chairs: Michael Thomas, Roman Thomas
	Caroline Dive: Circulating tumor cells in SCLC: opportunities for new therapeutic strategies
	Julie George: Acquired drug resistance in SCLC
	Anton Berns: Transcription factor alterations in SCLC
	Julien Sage: Kinase signaling networks in SCLC
1.00 pm	Concluding remarks: Charles Swanton, Roman Thomas, Reinhard Büttner, Jürgen Wolf
	1.10 - 2.00 pm: Lunch